Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBIT Margin (2024 - 2025)

Monte Rosa Therapeutics (GLUE) has 2 years of EBIT Margin data on record, last reported at 258.26% in Q3 2025.

  • For Q3 2025, EBIT Margin rose 2957.0% year-over-year to 258.26%; the TTM value through Sep 2025 reached 4.69%, up 86598.0%, while the annual FY2024 figure was 107.26%, N/A changed from the prior year.
  • EBIT Margin reached 258.26% in Q3 2025 per GLUE's latest filing, down from 67.06% in the prior quarter.
  • Across five years, EBIT Margin topped out at 51.85% in Q1 2025 and bottomed at 3284.49% in Q1 2024.